ArticleAdvances in experimental medicine and biology2026
Role of Mitochondrial Optical Redox Imaging in Modern Cancer Research (2024 Peter Vaupel Honorary Lecture).
Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The mitochondrial optical redox imaging (ORI), pioneered by the late Britton Chance and his coworkers starting from the 1950s, is mainly based on the intrinsic fluorescence of reduced nicotinamide adenine dinucleotide (NADH) and oxidized flavoproteins (Fp) containing flavin adenine dinucleotide (FAD). These two important metabolic coenzymes regulate many intracellular biochemical reactions including glycolysis, the Krebs cycle, and oxidative phosphorylation, and participate in the intricate interplay between metabolism and signaling. The optical redox ratio (ORR) of these two fluorescence signals is an indicator of mitochondrial metabolic and redox status. Chance and his coworkers not only studied redox status in cells and tissues based on the intrinsic fluorescence but also developed the Chance redox scanner in the 1970s-80s, which images the 3D distribution of NADH, Fp, and ORR ex vivo in snap-frozen tissues. The repertoire of ORI has been further strengthened and enriched with the modern technical advancements including state-of-the-art fluorescence, confocal, two-photon, and lifetime imaging microscopy. ORI has been extensively applied to (pre)cancer cells and tissues including clinical biopsies and patient tumor-derived organoids, to develop metabolic biomarkers for (pre)cancer diagnosis, prognosis, and treatment response. In this chapter, I illustrate the basic principles, main concepts and progresses, and future directions of ORI in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.